Erasca, Inc. Common Stock
ERAS •
Buy Open
Signal type
Buy
Status
Open
Open Price
$2.90
Stop Loss
$2.58
Performance
515.52%
Days Open
149
Signal Setup
Signal Type Buy
Status Open
Open Date Nov 17, 2025
Open Price $2.90
Stop Loss $2.58
Timespan Day
Company Profile
Name Erasca, Inc. Common Stock
Ticker ERAS
Market Cap $359.77M
Sector PHARMACEUTICAL PREPARATIONS
Latest Close $17.85
List Date Jul 16, 2021
Description
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
Website Open Company Website